ABLi Therapeutics is a developing small molecule inhibitors to treat diseases resulting from Abelson Tyrosine Kinase dysfunction (Abl kinases or c-Abl). The Company is engineering its Abl kinase inhibitors to treat Parkinson’s disease, Parkinson’s-related neurodegenerative diseases and other neurological diseases associated with Abl kinase dysfunction inside and outside of the brain.
Company Details
- Employees
- 2
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://ablitherapeutics.com
Abli Therapeutics Questions
Abli Therapeutics's website is https://ablitherapeutics.com
Abli Therapeutics's LinkedIn profile is https://www.linkedin.com/company/abli-therapeutics
Abli Therapeutics has
2 employees.
View email and phone details for 2
employees at Abli Therapeutics.
Abli Therapeutics's industry is
Biotechnology Research
Abli Therapeutics's top competitors are
Verastem Oncology,
Palvella Therapeutics,
Cvg Home Buyers Llc,
Inhibikase Therapeutics, Inc.,
Stylus Medicine,
Synthbiome Inc.,
Epivax Therapeutics, Inc.,
Remedy Plan Therapeutics,
Intrepid Labs,
Oruka Therapeutics.
Abli Therapeutics's categories are Biotechnology Research
